Use of vaginal suppositories: a therapeutic approach for vaginal infections

Vaginal infections are common across the lifespan. Most individuals with a vagina will experience at least one episode of a symptomatic vaginal infection, and many will experience recurrent episodes. Vaginal infections result from disturbances in the normal vaginal ecosystem — a dynamic balance of microorganisms, mucosal immunity, hormonal influences and local pH — that normally protects the lower genital tract. When this balance is disturbed, pathogenic or overgrowing organisms can produce symptoms such as abnormal discharge, odor, vulvar or vaginal irritation, and discomfort. Topical vaginal therapies, including vaginal suppositories (also called pessaries or vaginal tablets), are an important tool in the diagnosis-specific treatment of several common causes of vaginitis.

This article reviews the pathophysiology of common vaginal infections, indications for vaginal suppositories, types of agents available, clinical application and technique, safety and contraindications, strategies for recurrent disease, preventive measures, and when to seek medical care. Sources include professional clinical guidance and patient information resources from ACOG, the NIH/MedlinePlus, Mayo Clinic and Cleveland Clinic.

Vaginal ecology and common causes of infection

The healthy vaginal environment is dominated by lactobacilli, which help maintain an acidic pH (typically 3.8–4.5) through lactic acid production and contribute to colonization resistance against pathogens. Factors that disrupt this environment increase susceptibility to infection. Common precipitating factors include antibiotic exposure, hormonal changes (pregnancy, menstrual cycle variations, menopause), uncontrolled diabetes, immunosuppression, intravaginal products (douches, fragranced washes), and sexual activity patterns.

Common causes of symptomatic vaginitis include:

Vulvovaginal candidiasis (yeast infection): most frequently due to Candida albicans, but other Candida species may be involved. Symptoms typically include vulvar itching, burning, and curd-like discharge. (Mayo Clinic, ACOG) [1][2]

Bacterial vaginosis (BV): a polymicrobial shift characterized by loss of lactobacilli and overgrowth of anaerobic bacteria (e.g., Gardnerella vaginalis, Atopobium vaginae). Symptoms commonly include homogeneous, thin gray discharge and a characteristic fishy odor, especially after intercourse. (NIH, Mayo Clinic) [3][1]

Trichomoniasis: a sexually transmitted protozoal infection (Trichomonas vaginalis) that can produce frothy yellow-green discharge, vulvar irritation, and dyspareunia. (NIH, Cleveland Clinic) [3][4]

Atrophic vaginitis (vaginal atrophy): estrogen deficiency in peri- and postmenopausal individuals leads to thinning of the vaginal epithelium, decreased lubrication, higher pH and symptoms such as dryness, burning, dyspareunia and recurrent irritation. Topical estrogen is the primary treatment. (ACOG, Mayo Clinic) [2][1]

Accurate diagnosis relies on clinical history, examination, and basic office tests (vaginal pH, microscopic evaluation of vaginal secretions with saline and potassium hydroxide [KOH], and, where indicated, culture or nucleic acid amplification testing). BV is often diagnosed using Amsel criteria or Gram stain (Nugent score), while candidiasis is supported by microscopy with pseudohyphae or budding yeast and normal or slightly acidic pH. Trichomonas may be identified on wet mount, antigen testing or NAATs. (Mayo Clinic, NIH) [1][3]

What are vaginal suppositories and how do they work?

Vaginal suppositories (also called vaginal tablets, pessaries or intravaginal capsules) are solid or semi-solid dosage forms designed for intravaginal insertion. At body temperature they dissolve, releasing active medication directly at the site of infection. Advantages of topical intravaginal therapy include:

High local drug concentrations with limited systemic absorption, reducing systemic adverse effects and drug interactions.
Targeted therapy that acts directly on organisms or local mucosa.
Multiple formulation options and dosing regimens (single-dose, short-course, or multi-day regimens) to match the diagnosis and patient preference.

Common active agents in vaginal suppositories include:

Azole antifungals (imidazoles and triazoles): clotrimazole and miconazole are widely available in vaginal suppository and cream formulations for treatment of vulvovaginal candidiasis. These agents inhibit fungal ergosterol synthesis and are effective against Candida species causing typical yeast infections. (Mayo Clinic, NIH) [1][3]

Clindamycin and metronidazole intravaginal products: used for treatment of bacterial vaginosis in certain formulations (e.g., clindamycin vaginal ovules, metronidazole vaginal gel or suppositories). These antibacterial agents act against anaerobic bacteria associated with BV. (Mayo Clinic, Cleveland Clinic) [1][4]

Boric acid vaginal capsules: used as a non-antifungal acidic agent effective for some refractory or recurrent non-albicans Candida infections and as adjuvant therapy to restore vaginal acidity. Typically reserved for recurrent or treatment-refractory disease under clinician direction because oral ingestion is toxic and safety in pregnancy is limited. (NIH, Mayo Clinic) [3][1]

Vaginal estrogens: estradiol or conjugated estrogen vaginal tablets or rings are used for atrophic vaginitis to restore mucosal integrity and normalize pH. These are intravaginal products but are not antimicrobial. (ACOG, Mayo Clinic) [2][1]

Other supportive intravaginal agents under investigation or used adjunctively include probiotics (lactobacilli preparations) delivered intravaginally or orally with the aim of restoring lactobacilli-dominant flora. Evidence for efficacy is variable and evolving. (NIH) [3]

Selection of a specific intravaginal agent depends on the diagnosis. Antifungal suppositories are appropriate for documented or likely vulvovaginal candidiasis; antibacterial vaginal agents are indicated for BV in selected cases; estrogen is indicated for atrophic vaginitis.

Indications and evidence for vaginal suppositories

Vulvovaginal candidiasis: Topical azole therapy (intravaginal or topical creams) is recommended for uncomplicated cases. Over-the-counter intravaginal azoles (miconazole, clotrimazole) are effective in symptomatic relief and mycologic cure for most patients. Choice of single-dose versus multi-day regimen may be influenced by product availability and patient preference. For recurrent vulvovaginal candidiasis (defined as four or more episodes per year), suppressive regimens (e.g., weekly oral fluconazole for months) are used under clinician supervision; topical maintenance strategies may also be considered. (Mayo Clinic, ACOG, NIH) [1][2][3]

Bacterial vaginosis: First-line treatment traditionally includes oral or intravaginal antibiotics such as metronidazole or clindamycin. Intravaginal clindamycin ovules and intravaginal metronidazole formulations are effective alternatives to oral therapy and may be considered especially when systemic therapy is contraindicated or when local therapy is preferred. Recurrence is common, and prevention strategies include timely condom use and avoidance of douching. (NIH, Mayo Clinic) [1][3]

Trichomoniasis: Standard treatment is systemic (oral) metronidazole or tinidazole; intravaginal agents are generally not sufficient as monotherapy for trichomoniasis. Sexual partners should be treated to prevent reinfection. (NIH, Cleveland Clinic) [3][4]

Atrophic vaginitis: Low-dose vaginal estrogen (tablet, cream, or ring) is first-line therapy for symptomatic vulvovaginal atrophy. Vaginal estrogen restores trophic changes, reduces pH, and improves symptoms and recurrent irritation. These are available as intravaginal tablets or rings and are distinct from antimicrobial suppositories. (ACOG, Mayo Clinic) [2][1]

Evidence supports the use of intravaginal azoles for uncomplicated candidiasis and intravaginal antibiotics for BV in indicated cases; however, accurate diagnosis is crucial because empiric use of antifungal suppositories for non-fungal causes will not resolve BV or trichomoniasis and may delay appropriate therapy.

Practical technique: how to use vaginal suppositories

Proper administration technique improves efficacy and reduces local irritation. General steps for intravaginal suppository use include:

Read product instructions and confirm the indication with a clinician if uncertain.
Wash hands with soap and water before and after insertion.
If an applicator is provided, follow package instructions to load the tablet or capsule into the applicator. Many products can also be inserted with a finger if appropriate.
Assume a comfortable position (lying on back with knees bent, standing with one foot elevated, or squatting) to facilitate insertion.
Gently insert the suppository or tablet into the upper part of the vagina as directed by the product instructions — typically as far as is comfortable.
Remain lying down for a few minutes after insertion to allow the medication to melt and distribute.
Avoid unprotected sexual intercourse during treatment courses for BV or trichomoniasis and discuss partner treatment with your clinician where appropriate. For candidiasis, partner treatment is generally not required unless the partner is symptomatic.
Clean reusable applicators according to product labeling; disposable applicators should be discarded.
Complete the full course of therapy even if symptoms improve before treatment is finished.

For specific populations (pregnancy, breastfeeding, adolescents), follow clinician guidance regarding choice of agent and dosing.

Safety, side effects and contraindications

Vaginal suppositories are generally well tolerated. Most adverse effects are local and may include:

Burning, stinging, or local irritation.
Allergic or contact dermatitis to excipients or active agents (rare).
Increased vaginal discharge due to formulation base.
For boric acid, local irritation or systemic toxicity if ingested — boric acid should never be taken orally and should be used under medical supervision.

Systemic absorption of topical azoles (clotrimazole, miconazole) and intravaginal clindamycin or metronidazole is usually low; however, systemic side effects are possible, and oral agents may be preferred in severe or complicated infections. For example, systemic antifungals such as fluconazole have known systemic interactions and should be used with caution in individuals on interacting medications or with hepatic impairment. (Mayo Clinic, NIH)

Contraindications and precautions:

Pregnancy: Many topical azole antifungals applied intravaginally are considered appropriate for treatment of uncomplicated vulvovaginal candidiasis during pregnancy when used as directed (typically 7-day topical regimens). Oral fluconazole in pregnancy is generally avoided due to potential fetal risks with repeated or high doses; ACOG recommends topical azoles as first-line for candidiasis in pregnancy. Metronidazole oral therapy is considered safe for BV and trichomoniasis in pregnancy when indicated; however, some intravaginal agents lack robust pregnancy safety data — consult a provider before use. (ACOG, NIH) [2][3]

Allergy or hypersensitivity: History of allergy to an active agent or excipient mandates avoidance and selection of an alternative therapy.

Severe or complicated infection: If systemic symptoms (fever, pelvic pain), extensive vulvar swelling, or failure of topical therapy occur, systemic therapy and further evaluation are warranted.

Ingestion risk: Products such as boric acid are potentially toxic if swallowed and should have appropriate warnings.

Always consult a clinician before initiating therapy when pregnancy is suspected, in breastfeeding individuals, in recurrent disease, or when concomitant medical conditions (e.g., diabetes, immunosuppression) exist.

Over-the-counter versus prescription options

Many topical antifungal vaginal products are available over the counter (OTC) and include multiple formulations and durations (single-dose, 3-day, 7-day). These OTC agents commonly contain clotrimazole or miconazole. OTC products are appropriate for individuals with a prior clinician-confirmed diagnosis of uncomplicated vulvovaginal candidiasis who recognize their symptoms.

Prescription intravaginal options include higher-potency antifungals, clindamycin vaginal ovules for BV, metronidazole vaginal gel, boric acid capsules (often prescription or compounded), and vaginal estrogen preparations. Prescription therapy is indicated when:

Unclear diagnosis or differential includes BV or trichomoniasis.
Recurrent vulvovaginal candidiasis (≥4 episodes per year) requiring suppression or culture-guided therapy.
Pregnancy where product selection requires clinician input.
Failure of OTC therapy or severe symptoms.

Accurate self-assessment can be challenging; when in doubt, seek clinician evaluation.

Recurrent or refractory vaginitis: special considerations

Recurrent vulvovaginal candidiasis (RVVC) is defined as four or more symptomatic episodes in one year. Management strategies for RVVC include:

Confirmation of diagnosis with microscopy and/or culture to rule out non-albicans species that may be less responsive to azoles.
Suppressive therapy: oral fluconazole given weekly for 6 months is a common regimen for suppression under medical supervision; topical maintenance regimens may also be used for some patients.
Consideration of non-azole options for non-albicans Candida: boric acid vaginal capsules (under clinician supervision), nystatin, or other agents guided by susceptibility testing. (ACOG, NIH) [2][3]

Recurrent BV also presents therapeutic challenges; recurrence is common even after appropriate therapy. Maintenance strategies may include intermittent intravaginal metronidazole or use of topical clindamycin, and behavioral modifications to reduce recurrence risk. Probiotic therapy has been studied, but data are heterogeneous and practice patterns vary. (NIH, Mayo Clinic) [3][1]

When infections are refractory to standard therapy, referral to a gynecologist or infectious disease specialist is appropriate for culture, sensitivity testing, and consideration of rare organisms or noninfectious causes (e.g., dermatitis, lichen sclerosus, atrophic changes).

Prevention and lifestyle measures

While not all episodes are preventable, measures that support normal vaginal ecology can reduce infection risk:

Avoid douching and the use of fragranced or harsh soaps in the vulvovaginal area. The external vulva can be cleansed with mild, unscented soap and water; internal cleansing (douching) disrupts flora and is discouraged. (NIH, Mayo Clinic) [3][1]

Wear breathable cotton underwear and avoid prolonged wearing of damp clothing (wet swimsuits or workout clothes). Tight, non-breathable garments may increase humidity and favor fungal growth.

Maintain good glycemic control in individuals with diabetes, as hyperglycemia predisposes to candidal overgrowth.

Use condoms to reduce risk of sexually transmitted infections, and discuss partner evaluation and treatment when appropriate for trichomoniasis or other STIs.

Consider changing menstrual products promptly and avoiding prolonged tampon use.

For postmenopausal genital symptoms, consider low-dose vaginal estrogen as recommended by a clinician to restore mucosal health and prevent recurrent irritation and infections. (ACOG) [2]

Special populations

Pregnancy:

Uncomplicated vulvovaginal candidiasis in pregnancy is commonly treated with topical azole therapy (vaginal suppositories/creams) for an extended duration (e.g., 7 days). Oral fluconazole should generally be avoided in pregnancy. Discuss any treatment with an obstetric care provider. (ACOG, NIH) [2][3]

Adolescents:

Vaginal suppositories can be used in adolescents if clinically indicated; however, provider counseling regarding proper use and sexual health education is important. For sexually active adolescents with abnormal discharge, evaluation for STIs should be considered.

Postmenopausal individuals:

Vaginal atrophy requires estrogen therapy for symptomatic relief; intravaginal estrogen preparations (tablets, rings) are distinct from antimicrobial suppositories. A clinician should evaluate menopausal genitourinary symptoms to guide therapy. (ACOG) [2]

Immunocompromised:

Individuals with immunosuppression (e.g., HIV, chronic steroids) may have more severe or atypical presentations and may require systemic therapy and specialist input.

When to seek medical attention

Seek prompt medical evaluation if any of the following occur:

First episode of symptomatic vaginitis where you are uncertain of the cause.
Failure to improve after appropriate OTC or prescribed therapy within the expected timeframe (generally a few days to a week, depending on the regimen).
Recurrent episodes (≥4 per year).
Severe pain, fever, malodorous discharge with systemic symptoms, abnormal vaginal bleeding, or signs of pelvic infection.
Pregnancy, breastfeeding, or other significant medical conditions where medication safety must be reviewed.

A clinician may perform office testing (vaginal pH, saline and KOH microscopy), obtain samples for NAATs, cultures, or Gram stain, and prescribe the most appropriate therapy.

Storage, handling and disposal

Store vaginal suppositories according to product labeling — many require storage at room temperature away from moisture and heat; some may be stored in the refrigerator if stated.
Keep products out of reach of children and pets. Do not ingest vaginal suppositories; certain products (e.g., boric acid) are toxic if swallowed.
Dispose of single-use applicators and packaging per local guidance.

Summary and clinical advice

Vaginal suppositories are an effective targeted therapy for several vaginal conditions, most notably vulvovaginal candidiasis and, in selected cases, bacterial vaginosis. Appropriate use depends on accurate diagnosis, consideration of individual patient factors (pregnancy, comorbidities), and adherence to the full course of therapy. Intravaginal therapy offers high local concentrations with limited systemic exposure, but clinicians and patients must be aware of contraindications, potential side effects and the need to reassess if symptoms persist or recur. Preventive strategies — including avoiding douching and fragranced products, practicing good glycemic control, and seeking timely care — can reduce the incidence of symptomatic infections.

If you are experiencing symptoms suggestive of a vaginal infection, consult a healthcare professional for diagnosis and individualized treatment recommendations.

References

Mayo Clinic. Yeast infection (vaginal). https://www.mayoclinic.org/diseases-conditions/yeast-infection/symptoms-causes/syc-20377463

American College of Obstetricians and Gynecologists (ACOG). Patient education and practice resources on vaginitis and vulvovaginal candidiasis. https://www.acog.org/womens-health/faqs/vaginitis

National Library of Medicine / MedlinePlus and NIH resources. Vaginitis and bacterial vaginosis overview. https://medlineplus.gov/vaginitis.html https://www.nichd.nih.gov/health/topics/bacterialvaginosis

Cleveland Clinic. Trichomoniasis. https://my.clevelandclinic.org/health/diseases/14958-trichomoniasis

(Information in this article is educational and not a substitute for individualized medical evaluation. For personalized diagnosis and treatment, please consult your healthcare provider.)